INNO-GENE SA ZY -10 (F:WQ3) — Market Cap & Net Worth
Market Cap & Net Worth: INNO-GENE SA ZY -10 (WQ3)
INNO-GENE SA ZY -10 (F:WQ3) has a market capitalization of $14.88 Million (€12.73 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #25847 globally and #2229 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INNO-GENE SA ZY -10's stock price €0.38 by its total outstanding shares 33581081 (33.58 Million).
INNO-GENE SA ZY -10 Market Cap History: 2021 to 2026
INNO-GENE SA ZY -10's market capitalization history from 2021 to 2026. Data shows change from $175.18 Million to $14.88 Million (-38.96% CAGR).
INNO-GENE SA ZY -10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INNO-GENE SA ZY -10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of WQ3 by Market Capitalization
Companies near INNO-GENE SA ZY -10 in the global market cap rankings as of May 5, 2026.
Key companies related to INNO-GENE SA ZY -10 by market ranking:
- Linde plc Ordinary Shares (NASDAQ:LIN): Ranked #92 globally with a market cap of $210.18 Billion USD.
- Air Liquide SA (PA:AI): Ranked #223 globally with a market cap of $108.00 Billion USD ( €92.38 Billion EUR).
- AIR LIQUIDE ADR 1/5/EO 11 (F:AILA): Ranked #231 globally with a market cap of $103.86 Billion USD ( €88.84 Billion EUR).
- Sherwin-Williams Co (NYSE:SHW): Ranked #339 globally with a market cap of $76.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #92 | Linde plc Ordinary Shares | NASDAQ:LIN | $210.18 Billion | $493.55 |
| #223 | Air Liquide SA | PA:AI | $108.00 Billion | €177.64 |
| #231 | AIR LIQUIDE ADR 1/5/EO 11 | F:AILA | $103.86 Billion | €36.60 |
| #339 | Sherwin-Williams Co | NYSE:SHW | $76.97 Billion | $310.49 |
INNO-GENE SA ZY -10 Historical Marketcap From 2021 to 2026
Between 2021 and today, INNO-GENE SA ZY -10's market cap moved from $175.18 Million to $ 14.88 Million, with a yearly change of -38.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €14.88 Million | 0.00% |
| 2025 | €14.88 Million | -4.29% |
| 2024 | €15.55 Million | -12.00% |
| 2023 | €17.67 Million | -63.41% |
| 2022 | €48.29 Million | -72.43% |
| 2021 | €175.18 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of INNO-GENE SA ZY -10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.88 Million USD |
| MoneyControl | $14.88 Million USD |
| MarketWatch | $14.88 Million USD |
| marketcap.company | $14.88 Million USD |
| Reuters | $14.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INNO-GENE SA ZY -10
HyEnergy S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of HPV-dependent solid tumors. In addition, it provides DNA analysis and genetic diseases dia… Read more